 | |||||
| lose weight | |||||
| NEWS | |||||
| GI Safety Similar for Popular Weight-Loss Drugs - Medscape Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes, a comparative cohort ...
| |||||
| Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings ... The study further showed that patients taking CONTRAVE had an average weight loss of 9.5% at 56 weeks compared to 2.7% for placebo (p <0.0001). "Food ...
| |||||
| See more results | Edit this alert | |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
